1. Home
  2. NUR vs ADVB Comparison

NUR vs ADVB Comparison

Compare NUR & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuran Wireless Inc. Common Shares

NUR

Nuran Wireless Inc. Common Shares

N/A

Current Price

$0.40

Market Cap

7.8M

Sector

N/A

ML Signal

N/A

ADVB

Advanced Biomed Inc.

N/A

Current Price

$2.44

Market Cap

8.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NUR
ADVB
Founded
N/A
2014
Country
Canada
Hong Kong
Employees
N/A
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.8M
8.6M
IPO Year
2016
2023

Fundamental Metrics

Financial Performance
Metric
NUR
ADVB
Price
$0.40
$2.44
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 446.6K
68.4K
Earning Date
08-28-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 3431.25
EPS
★ N/A
N/A
Revenue
N/A
★ $127,637.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$0.60
Revenue Growth
N/A
N/A
52 Week Low
$0.36
$1.80
52 Week High
$7.72
$113.80

Technical Indicators

Market Signals
Indicator
NUR
ADVB
Relative Strength Index (RSI) 25.39 36.78
Support Level $0.36 $1.80
Resistance Level $0.83 $5.59
Average True Range (ATR) 0.09 0.53
MACD 0.00 0.17
Stochastic Oscillator 8.97 23.26

Price Performance

Historical Comparison
NUR
ADVB

About NUR Nuran Wireless Inc. Common Shares

Nuran Wireless Inc is engaged in the Network as a Service (NAAS) business. The group operates in the research, development, manufacturing, marketing, and operation of digital electronic circuits and wireless telecommunication products and offers services in the mobile telephony industry. It also provides products and services that help mobile network operators profitably serve off-grid markets that are currently not served. It has two reportable segments: NaaS and Direct Sales. The majority of the revenue is derived from Africa.

About ADVB Advanced Biomed Inc.

Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.

Share on Social Networks: